BCL3 and breast cancer: Interestingly, high Bcl3 expression was shown to correlate with reduced relapse-free survival (RFS) in breast cancer patients with tumours harbouring p53 mutations, suggesting that these patients may benefit most from Bcl3 targeting therapies.